Artemisinin - CAS 63968-64-9
Catalog number: 63968-64-9
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C15H22O5
Molecular Weight:
282.33
COA:
Inquire
Targets:
HCV
Description:
Artemisinin is a drug used to treat multi-drug resistant strains of falciparum malaria.
Purity:
>98%
MSDS:
Inquire
InChIKey:
BLUAFEHZUWYNDE-NNWCWBAJSA-N
InChI:
InChI=1S/C15H22O5/c1-8-4-5-11-9(2)12(16)17-13-15(11)10(8)6-7-14(3,18-13)19-20-15/h8-11,13H,4-7H2,1-3H3/t8-,9-,10+,11+,13-,14-,15-/m1/s1
Canonical SMILES:
CC1CCC2C(C(=O)OC3C24C1CCC(O3)(OO4)C)C
1.Efficacy of Artesunate-mefloquine for Chloroquine-resistant Plasmodium vivax Malaria in Malaysia: An Open-label, Randomized, Controlled Trial.
Grigg MJ1, William T2, Menon J3, Barber BE1, Wilkes CS1, Rajahram GS4, Edstein MD5, Auburn S6, Price RN7, Yeo TW8, Anstey NM9. Clin Infect Dis. 2016 Apr 22. pii: ciw121. [Epub ahead of print]
BACKGROUND:  Chloroquine (CQ)-resistant Plasmodium vivax is increasingly reported throughout southeast Asia. The efficacy of CQ and alternative artemisinin combination therapies (ACTs) for vivax malaria in Malaysia is unknown.
2.Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/β-catenin signaling.
Tong Y1,2, Liu Y1,2, Zheng H2, Zheng L1,2, Liu W1,2, Wu J2, Ou R2, Zhang G2, Li F2, Hu M2,3, Liu Z1,2, Lu L2. Oncotarget. 2016 Apr 22. doi: 10.18632/oncotarget.8920. [Epub ahead of print]
Non-small-cell lung cancer (NSCLC) is the most prevalent malignancy worldwide given its high incidence, considerable mortality, and poor prognosis. The anti-malaria compounds artemisinin (ART), dihydroartemisinin (DHA), and artesunate (ARTS) reportedly have anti-cancer potential, although the underlying mechanisms remain unclear. In this work, we used flow cytometry to show that ART, DHA, and ARTS could inhibit the proliferation of A549 and H1299 cells by arresting cell cycle in G1 phase. Meanwhile, tumor malignancy including migration, invasion, cancer stem cells, and epithelial-mesenchymal transition were also significantly suppressed by these compounds. Furthermore, ART, DHA, and ARTS remarkably decreased tumor growth in vivo. By using IWP-2, the inhibitor of Wnt/β-catenin pathway, and Wnt5a siRNA, we found that ART, DHA, and ARTS could render tumor inhibition partially dependent on Wnt/β-catenin inactivation. These compounds could strikingly decrease the protein level of Wnt5-a/b and simultaneously increase those of NKD2 and Axin2, ultimately resulting in β-catenin downregulation.
3.Artesunate inhibits adipogeneis in 3T3-L1 preadipocytes by reducing the expression and/or phosphorylation levels of C/EBP-α, PPAR-γ, FAS, perilipin A, and STAT-3.
Jang BC1. Biochem Biophys Res Commun. 2016 Apr 21. pii: S0006-291X(16)30614-3. doi: 10.1016/j.bbrc.2016.04.109. [Epub ahead of print]
Differentiation of preadipocyte, also called adipogenesis, leads to the phenotype of mature adipocyte. However, excessive adipogenesis is closely linked to the development of obesity. Artesunate, one of artemisinin-type sesquiterpene lactones from Artemisia annua L., is known for anti-malarial and anti-cancerous activities. In this study, we investigated the effect of artesunate on adipogenesis in 3T3-L1 preadipocytes. Artesunate strongly inhibited lipid accumulation and triglyceride (TG) synthesis during the differentiation of 3T3-L1 preadipocytes into adipocytes at 5 μM concentration. Artesunate at 5 μM also reduced not only the expressions of CCAAT/enhancer-binding protein-α (C/EBP-α), peroxisome proliferator-activated receptor-γ (PPAR-γ), fatty acid synthase (FAS), and perilipin A but also the phosphorylation levels of signal transducer and activator of transcription-3 (STAT-3) during adipocyte differentiation. Moreover, artesunate at 5 μM reduced leptin, but not adiponectin, mRNA expression during adipocyte differentiation.
4.Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/β-catenin signaling.
Tong Y1,2, Liu Y1,2, Zheng H2, Zheng L1,2, Liu W1,2, Wu J2, Ou R2, Zhang G2, Li F2, Hu M2,3, Liu Z1,2, Lu L2. Oncotarget. 2016 Apr 22. doi: 10.18632/oncotarget.8920. [Epub ahead of print]
Non-small-cell lung cancer (NSCLC) is the most prevalent malignancy worldwide given its high incidence, considerable mortality, and poor prognosis. The anti-malaria compounds artemisinin (ART), dihydroartemisinin (DHA), and artesunate (ARTS) reportedly have anti-cancer potential, although the underlying mechanisms remain unclear. In this work, we used flow cytometry to show that ART, DHA, and ARTS could inhibit the proliferation of A549 and H1299 cells by arresting cell cycle in G1 phase. Meanwhile, tumor malignancy including migration, invasion, cancer stem cells, and epithelial-mesenchymal transition were also significantly suppressed by these compounds. Furthermore, ART, DHA, and ARTS remarkably decreased tumor growth in vivo. By using IWP-2, the inhibitor of Wnt/β-catenin pathway, and Wnt5a siRNA, we found that ART, DHA, and ARTS could render tumor inhibition partially dependent on Wnt/β-catenin inactivation. These compounds could strikingly decrease the protein level of Wnt5-a/b and simultaneously increase those of NKD2 and Axin2, ultimately resulting in β-catenin downregulation.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related HCV Products


CAS 1350462-55-3 MK-5172 hydrate

MK-5172 hydrate
(CAS: 1350462-55-3)

In biochemical assays, MK-5172 was effective against a panel of major genotypes and variants engineered with common resistant mutations observed in clinical stu...

CAS 691852-58-1 Nesbuvir

Nesbuvir
(CAS: 691852-58-1)

Nesbuvir, a novel selective nonstructural protein 5B (NS5B) polymerase inhibitor, acts as candidate for HCV treatment. It was reduced across different isolates.

Faldaprevir
(CAS: 801283-95-4)

Faldaprevir, also called as BI 201335, is a potent, once-daily (QD), hepatitis C virus (HCV) NS3/4A protease inhibitor with the potential to treat HCV infection...

CAS 690270-29-2 Balapiravir

Balapiravir
(CAS: 690270-29-2)

Balapiravir is the prodrug of a nucleoside analogue inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase. It is the tri-isobutyrate ester prodr...

BMS-890068

BMS-890068 is an acyclic P1 bi-cyclopropaneacylsulfonamidetripeptide that can be used as hepatitis C virus (HCV) NS3 protease inhibitor.

CAS 630420-16-5 Asunaprevir

Asunaprevir
(CAS: 630420-16-5)

Asunaprevir is a potent hepatitis C virus (HCV) non-structural protein protease inhibitor currently in Phase III clinical trials for the treatment of HCV infect...

CAS 940908-79-2 R-7128

R-7128
(CAS: 940908-79-2)

R-7128 is a selective nucleoside analog inhibitor of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, with activity across all HCV genotypes. It i...

Vedroprevir
(CAS: 1098189-15-1)

Vedroprevir is a selective hepatitis C virus (HCV) NS3 protease inhibitor. It is a pharmaceutical drug that is used in the treatment of hepatitis C virus in pat...

CAS 923590-37-8 Vaniprevir

Vaniprevir
(CAS: 923590-37-8)

Vaniprevir is a non-covalent competitive inhibitor of the hepatitis C virus (HCV) NS3/4A protease. It is a macrocyclic hepatitis C virus NS3/4a protease inhibit...

CAS 1009119-65-6 Daclatasvir dihydrochloride

Daclatasvir dihydrochloride
(CAS: 1009119-65-6)

Daclatasvir dihydrochloride is a highly selective inhibitor of HCV NS5A with EC50 of 9-50 pM, for a broad range of HCV replicon genotypes and the JFH-1 genotype...

CAS 394730-60-0 Boceprevir

Boceprevir
(CAS: 394730-60-0)

An NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection.

Ombitasvir
(CAS: 1258226-87-7)

Ombitasvir, a NS5A inhibitor, could be effective in the treatment of HCV as an antiviral agent. IC50: 14 pM and 5 pM (EC50) for genotype 1a-H77 and 1b-Con1 resp...

CAS 1026785-59-0 VX-222 (VCH-222, Lomibuvir)

VX-222 (VCH-222, Lomibuvir)
(CAS: 1026785-59-0)

VX-222 (VCH-222) is a novel, potent and selective inhibitor of HCV polymerase with IC50 of 0.94-1.2 μM, 15.3-fold less effective for mutant M423T, and 108-fold ...

CAS 1009734-33-1 HZ-1157

HZ-1157
(CAS: 1009734-33-1)

HZ-1157 is an inhibitor of hepatitis C virus (HCV) nonstructural protein 3/4A (NS3/4A) protease.

CAS 1256388-51-8 Ledipasvir

Ledipasvir
(CAS: 1256388-51-8)

Ledipasvir (GS5885) is a HCV NS5A polymerase inhibitor, used for the treatment of hepatitis C virus infection.

CAS 923604-59-5 Simeprevir

Simeprevir
(CAS: 923604-59-5)

Simeprevir plays an important role in HCV replication. Data from phase I and II clinical trials of TMC-435350 (TMC 435350; TMC 435; TMC-435350) to date have sho...

GSK-2818713

GSK-2818713 is a second-generation inhibitor of hepatitis C virus (HCV) NS5A replication. Compared to daclatasvir, a first-generation NS5A replication complex i...

CAS 1009119-64-5 Daclatasvir

Daclatasvir
(CAS: 1009119-64-5)

Daclatasvir, inhibits the HCV protein NS5A, and thus can be used as a drug candidate for the treatment of hepatitis C (HCV).

CAS 81485-25-8 Peretinoin

Peretinoin
(CAS: 81485-25-8)

Peretinoin, also known as NIK-333, orally available, acyclic retinoid with potential antineoplastic and chemopreventive activities. Peretinoin binds to and acti...

CAS 850876-88-9 Danoprevir

Danoprevir
(CAS: 850876-88-9)

Danoprevir(ITMN-191;R7227; RO5190591;RG7227) is a peptidomimetic inhibitor of the NS3/4A protease of hepatitis C virus (HCV) with IC50 of 0.2-3.5 nM, inhibition...

Chemical Structure

CAS 63968-64-9 Artemisinin

Quick Inquiry

Verification code

Featured Items